Immunovant, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMVT research report →
Range $40 – $40
Price Chart
About the company
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody.
- CEO
- Eric Venker
- IPO
- 2019
- Employees
- 315
- HQ
- Durham, NY, US
Get TickerSpark's AI analysis on IMVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.57B
- P/E
- -12.97
- Fwd P/E
- 63.97
- PEG
- -1.36
- P/S
- 968.67
- P/B
- 10.45
- EV/EBITDA
- -12.06
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -7488.36%
- Net Margin
- -7173.52%
- ROE
- -63.01%
- ROIC
- -80.67%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-532,902,000
- Net Income
- $-505,606,000-22.2%
- EPS
- $-2.77-1.5%
- OCF Growth
- -8.4%
- FCF Growth
- -8.1%
- 52W High
- $45.42
- 52W Low
- $21.86
- 50D MA
- $32.17
- 200D MA
- $32.49
- Beta
- 0.84
- RSI (14)
- 50
- Avg Volume
- 1.42M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Roivant reported a transformational quarter, highlighted by the early commercial launch of LISRAYA, positive Phase 2 data for IMVT-1402 in refractory RA, and continued momentum across brepocitinib and mosliciguat programs.· November 9, 2026
- LISRAYA generated $31 million of net revenue in its first five weeks on the market, with management saying there were hundreds of patients on paid drug at quarter-end and many hundreds now.
- IMVT-1402’s RA study hit its Period 2 primary endpoint: about 92.5% of patients on 600 mg maintained ACR20 versus about 75% on placebo, while 300 mg looked similar to placebo.
- Management said 1402 showed no new safety signals and that deeper IgG suppression appears to matter, with 600 mg outperforming 300 mg across response measures.
- Brepocitinib in noninfectious uveitis met the primary endpoint and all secondary endpoints in both studies, and mosliciguat posted a 56% placebo-adjusted PVR reduction in PH-ILD.
- Cash was $4.2 billion at September 30, and the company repurchased about $280 million of stock in the first six months of the year.
Roivant reported $31 million of net revenue from LISRAYA in the quarter, reflecting roughly five weeks of commercialization after approval in August. Net loss from continuing operations was $153 million, or $133 million non-GAAP, and cash was $4.2 billion as of September 30. On IMVT-1402 in refractory RA, Period 2 showed about 92.5% ACR20 maintenance on 600 mg versus roughly 75% on placebo; 300 mg was not enough to preserve the response and looked similar to placebo. Management did not give full-year or next-quarter financial guidance, but said there could be a modest headwind from LISRAYA inventory dynamics in the December quarter and that inventory effects should fade next year. For the pipeline, management said FDA discussions on 1402 are ongoing and that a plan for next-stage RA development will be shared later this year or early next year; the company also expects an sNDA filing for NIU and multiple additional program/indication updates in 2027.
Matt Gline’s tone was highly upbeat and celebratory, calling it a “phenomenal” and “transformational” year. He emphasized that Roivant is seeing real clinical and commercial validation across multiple programs, especially the LISRAYA launch, brepocitinib in NIU, and mosliciguat in PH-ILD. On 1402, he highlighted that the new RA data reinforce the importance of deep IgG suppression and could support a meaningful future franchise, while noting that regulatory discussions are still ongoing.
The call included limited formal CFO detail; management instead gave a brief financial update from the CEO. Roivant said expenses were relatively consistent with expectations, net loss from continuing operations was $153 million, or $133 million non-GAAP, and cash stood at $4.2 billion as of September 30, helped by Moderna litigation receipts over the summer. The company also said it repurchased about $280 million of stock, or about 9.4 million shares, in the six months ended 9/30.
Analysts focused on LISRAYA’s early paid-Rx conversion, inventory/stocking effects, and payer access; management said the launch is still early, access has been generally straightforward so far, and stocking created a tailwind in the September quarter with a likely modest headwind in December. On 1402, analysts asked whether one Phase III might be enough, what endpoint and design FDA might prefer, and whether the program could expand beyond the current refractory RA population; management said it does not know yet, expects a straightforward randomized controlled trial rather than another randomized-withdrawal study, and wants first to get the drug to this high-unmet-need population. Management also said Sjögren’s is probably not moving forward given competitor results and recent field updates, while Graves’ enrollment remains strong and timing updates are expected soon.
The call suggests Roivant has multiple shots on goal with real near-term execution: a newly launched product already producing $31 million in net revenue, strong physician and patient uptake, and several late-stage or near-late-stage pipeline catalysts ahead. Management believes 1402’s RA data and brepocitinib’s NIU and mosliciguat’s PH-ILD results could support important new products or indications, and they repeatedly said the data are clinically meaningful and well received.
The biggest risks discussed were early launch uncertainty for LISRAYA, especially around payer tightening and quarter-to-quarter inventory noise, and the fact that the company is still early in building durable commercial coverage. For 1402, the path forward remains dependent on ongoing FDA discussions, with no confirmation yet on endpoint, trial design, or whether a single Phase III would be enough. Management also said Sjögren’s is unlikely to advance, and that some programs still face competitive and regulatory uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 41.1%
- Shares Outstanding
- 206.95M
- Float Shares
- 84.99M
of shares held by institutions
240 13F filers
Buy/sell ratio 0.18. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 15.70M | ▼ 482.31K |
| Deep Track Capital, LP | 9.16M | ▼ 180.35K |
| Vanguard Group Inc | 7.78M | ▲ 952.50K |
| Blackrock, Inc. | 7.43M | ▲ 244.87K |
| Farallon Capital Management, L.L.C. | 6.47M | ▲ 666.00K |
| Morgan Stanley | 5.68M | ▲ 1.15M |
| Two Seas Capital LP | 4.61M | ▲ 1.46M |
| Tcg Crossover Management, LLC | 4.46M | 0 |
| Vanguard Portfolio Management LLC | 4.26M | ▲ 354.23K |
| State Street Corp | 4.20M | ▼ 420.56K |
| Vanguard Capital Management LLC | 4.09M | ▲ 448.56K |
| Rtw Investments, LP | 3.18M | 0 |
Held by 335 ETFs
Biggest fund positions in IMVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Pande Atul | other | 3,000 |
| Nov 11, 26 | Pande Atul | sell | 3,000 |
| Nov 11, 26 | Pande Atul | other | 3,000 |
| Oct 28, 26 | Girao Tiago | sell | 6,606 |
| Oct 21, 26 | Stout Jay S | sell | 2,595 |
| Oct 7, 26 | Stout Jay S | sell | 2,213 |
| Oct 7, 26 | Stout Jay S | sell | 1,596 |
| Oct 7, 26 | Van Tuyl Christopher | sell | 1,327 |
| Oct 7, 26 | Gloria Melanie | sell | 2,241 |
| Oct 1, 26 | Venker Eric | other | 92,187 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMVT coverage
Recent articles, reports, and earnings notes.

Lycia Therapeutics Prices Its IPO: A Big Bet on Protein Degradation
Lycia Therapeutics Inc. is set to list on Nasdaq on 2026-10-23, and the company has priced its IPO with 17,640,000 shares offered; the price range was not disclosed. The setup is compelling for investors who want exposure to early-stage biotech, but the story still hinges on clinical execution and platform validation.

Should You Buy the Electra Therapeutics IPO? Here's the Setup
Electra Therapeutics is expected to list on NASDAQ on 2026-09-18 in a $14.00 to $16.00 range. The company is offering 21,666,667 shares under ticker ETRA. The bull case is a first-in-class immune-cell depletion platform; the bear case is a clinical-stage biotech with no revenue and rising losses.

Attovia Therapeutics IPO: What Investors Need to Know
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.
Want a deeper read on IMVT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
zacks.com · Nov 11
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
seekingalpha.com · Nov 11
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
zacks.com · Nov 11
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 9
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
benzinga.com · Nov 9
What Immunovant (IMVT) Said on Its Q2 Earnings Call
marketbeat.com · Nov 9
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
globenewswire.com · Nov 9
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.